Credit: Bo Jungmayer/Fred Hutch News Service
Study co-author Dr. Gary Lyman says: “For many women with early-stage breast cancer, advanced imaging and serial tumor markers add cost but not value. In some cases, they can even lead to unnecessary invasive procedures, excessive radiation exposure, misdiagnosis and even overtreatment.” Dr. Lyman is a breast cancer oncologist, health economist and co-director of the Hutchinson Institute for Cancer Outcomes Research, or HICOR.